Jakavi 5mg Tablet

Introduction

Jakavi is a prescription medication that contains the active ingredient Ruxolitinib. It is available in tablet form and is used to treat certain types of blood disorders and cancers.

Uses

Jakavi is primarily prescribed to patients with myelofibrosis, a rare bone marrow disorder that disrupts the normal production of blood cells. It is also used to treat polycythemia vera, a condition characterized by the overproduction of red blood cells, and acute graft-versus-host disease, a complication that can occur after a stem cell transplant.

Dosage and Administration

The dosage of Jakavi will vary depending on the specific condition being treated, as well as other individual factors. Follow the instructions provided by your healthcare professional. Generally, the recommended starting dose is 15 mg taken orally twice daily. Your doctor may adjust the dose based on your response to the medication. The tablets should be swallowed whole with a glass of water and can be taken with or without food.

Mechanism of Action

Ruxolitinib, the active ingredient in Jakavi, works by inhibiting certain enzymes that are involved in the abnormal growth and survival of cells in the bone marrow. By blocking these enzymes, the medication helps to reduce the symptoms associated with myelofibrosis, polycythemia vera, and acute graft-versus-host disease.

Side Effects

Common side effects may include headache, dizziness, fatigue, nausea, and diarrhea. These side effects are usually mild and may subside over time. However, if they persist or worsen, consult your healthcare professional.

Serious side effects are rare but may include serious infections, anemia, low platelet count, and liver problems. If you experience any signs of infection such as fever, chills, or persistent cough, or if you notice unusual bleeding or bruising, yellowing of the skin or eyes, or abdominal pain, seek medical attention immediately.

Drug Interactions

inform your healthcare professional about all the medications you are currently taking, as well as any herbal supplements or over-the-counter drugs, before starting Jakavi. Certain medications may interact with Ruxolitinib, potentially affecting its effectiveness or increasing the risk of side effects. Discuss with your doctor or pharmacist to ensure the safe use of this medication.

Precautions

Before taking Jakavi, inform your healthcare professional if you have any existing medical conditions, especially liver or kidney problems. This medication may not be suitable for patients with certain conditions or those taking certain medications.

Jakavi should not be taken by pregnant or breastfeeding women, as it may harm the unborn baby or pass into breast milk. Use effective contraception while taking this medication.

Storage

Jakavi should be stored at room temperature, away from moisture and heat. Keep it out of the reach of children and pets. Do not use the medication if it has expired or if the packaging is damaged.

Patient Tips

• Follow the prescribed dosage and administration instructions provided by your healthcare professional.
• If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and resume your regular dosing schedule.
• Do not stop taking Jakavi without consulting your healthcare professional, as this may affect the effectiveness of the treatment.
• If you have any questions or concerns about the medication or its side effects, discuss them with your healthcare professional.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Jakavi 10mg Tablets (Health Professionals SmPC) Available at:
• Ruxolitinib (Drugs.com) [Accessed 30 Jun. 2024] (online) Available at:
• ruxolitinib 1.5 % topical cream (RX) [Accessed 22 Jun. 2024] (online) Available at:
• Ruxolitinib (MedlinePlus) [Accessed 0 Jun. 2024] (online) Available at:
• Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis. J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20. [Accessed 15 Jun. 2024] Available at: